Multihance (Gadobenate Dimeglumine)

Gadobenate dimeglumine, the active ingredient in Multihance, is a gadolinium-based contrast agent presented as a 0.5 mmol/mL injection solution for intravenous use. It enhances magnetic resonance imaging of specific organ systems in patients undergoing diagnostic scans.

GNH USA supplies Multihance as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Multihance is used as a gadolinium‑based contrast agent to improve magnetic resonance imaging of various organ systems.

Central nervous system MRI: provides enhanced visualization of brain and spinal cord structures for diagnostic assessment. Liver MRI: improves detection and characterization of focal hepatic lesions. Cardiovascular MRI: highlights vascular anatomy and myocardial perfusion for functional evaluation. Musculoskeletal MRI: increases contrast between bone, cartilage, and soft‑tissue structures for accurate diagnosis.

Adverse reactions may occur following administration of Multihance.

Common Side Effects: - Warmth or flushing sensation at the injection site - Nausea or mild vomiting - Headache - Dizziness or light‑headedness - Transient metallic taste - Mild injection‑site pain

Serious or Rare Side Effects: - Severe allergic reactions including anaphylaxis - Nephrogenic systemic fibrosis in patients with severe renal impairment - Acute hypotension or cardiovascular collapse - Cardiac arrest (rare) - Severe respiratory distress - Persistent skin rash or urticaria

Multihance should be used with attention to patient safety and handling requirements.

Renal function assessment: evaluate kidney function before administration. Pregnancy considerations: safety not established; use only if essential. Allergy screening: avoid in patients with known hypersensitivity to gadolinium agents. Severe renal impairment: contraindicated due to NSF risk. Hydration status: ensure adequate hydration to support renal clearance. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be reviewed prior to use.

Major Interactions (Avoid): - Other gadolinium‑based contrast agents: cumulative exposure may increase NSF risk. - Nephrotoxic medications (e.g., aminoglycosides, high‑dose NSAIDs): may exacerbate renal dysfunction. - High‑dose intravenous iron: can interfere with MRI interpretation.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask early signs of hypersensitivity. - Diuretics: affect fluid balance during contrast administration. - Antihistamines: may reduce efficacy of pre‑medication protocols.